EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pattern of Occurrence and Management of Dual Malignancy: Our Institutional Experience

Pragya Singh, Atokali Chophy, Aviral Rastogi, Debanjan Sikdar, Sweety Gupta, Rachit Ahuja, Deepa Joseph, Prashant Durgapal, Amit Gupta, Manoj Kumar Gupta

Reports of Radiotherapy and Oncology · 2023

DOI: 10.5812/rro-140352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Reports of Radiotherapy and Oncology, 2023. Verfasst von Pragya Singh und 9 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Management of dual malignancies is challenging in the present scenario of advanced techniques and increased life expectancy.

Objectives

To determine the demographic and clinical profile of patients with dual malignancies and the management received.

Methods

In this retrospective analysis of the data of patients presenting with histologically proven synchronous or metachronous dual malignancy, we evaluated the demographic and clinical profile of patients with dual malignancies and the management received.

Results

In this study, 158 cases with multiple primary cancers, of whom 57 were synchronous and 101 were metachronous, were observed from January 2017 to December 2021. The maximum period for synchronous tumor occurrence was seen at 6 months (180 days). The interval of occurrence of metachronous tumors ranged from 1 to 15 years, with an average of 4.8 years for the entire group. Moreover, 73 (46.2%) were females, and 85 (53.8%) were males, with a male-to-female ratio of 1.2: 1. The most common site of primary tumor with dual malignancies was the head and neck (31%), followed by breast cancers (21%). The most frequent pathologic type was adenocarcinoma (40%), followed by squamous carcinoma (38%), hematopoietic and lymphoid tissues (7.5%), transitional cell carcinoma (6.3%), sarcomas and soft tissue tumors (2.5%).

Conclusions

Even in complete clinical remission, every cancer patient must take into account the possibility of developing a second malignancy and must be closely monitored.

Zitieren

APA

Singh, P., Chophy, A., Rastogi, A., Sikdar, D., Gupta, S., Ahuja, R., Joseph, D., Durgapal, P., Gupta, A., & Gupta, M. K. (2023). Pattern of Occurrence and Management of Dual Malignancy: Our Institutional Experience. Reports of Radiotherapy and Oncology. https://doi.org/10.5812/rro-140352

Vancouver

Singh P, Chophy A, Rastogi A, Sikdar D, Gupta S, Ahuja R, et al. Pattern of Occurrence and Management of Dual Malignancy: Our Institutional Experience. Reports of Radiotherapy and Oncology. 2023. doi:10.5812/rro-140352

BibTeX
@article{Singh2023,
  author = {Singh, Pragya and Chophy, Atokali and Rastogi, Aviral and Sikdar, Debanjan and Gupta, Sweety and Ahuja, Rachit and Joseph, Deepa and Durgapal, Prashant and Gupta, Amit and Gupta, Manoj Kumar},
  title = {Pattern of Occurrence and Management of Dual Malignancy: Our Institutional Experience},
  journal = {Reports of Radiotherapy and Oncology},
  year = {2023},
  doi = {10.5812/rro-140352}
}
Kostenlos starten →